USA News Group Commentary VANCOUVER, BC, May 28, 2024 /PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher anal cancer mortality for women. Worldwide, improved access to testing led to a 4.2% increase in HIV diagnoses in the EU and a whopping 120% increase in Montreal, Canad ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landscape, offering patients innovati ...

Core Insights - Oncolytics Biotech Inc. presented two abstracts at the 2024 ASCO Annual Meeting, focusing on the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma (PDAC) and its immunotherapeutic mechanism [1][2] Group 1: Study Details - The GOBLET study's cohort 5 will evaluate pelareorep combined with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic PDAC patients [1][4] - The study employs a Simon two-stage design, with Stage 1 involving 15 evaluable patients per treatment arm [4][5] - Co-primary endpoints include objective response rate and safety, with secondary endpoints assessing progression-free and overall survival [4][5] Group 2: Funding and Enrollment - The GOBLET cohort is funded by a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) [2] - Enrollment for this cohort is expected to begin in the current quarter [2] Group 3: Mechanism of Action - Pelareorep stimulates a proinflammatory response, enhancing both innate and adaptive immune responses, which may improve treatment outcomes [2][10] - The second abstract highlights pelareorep's ability to expand tumor-infiltrating lymphocytes (TILs), correlating TIL expansion with tumor response [2][10] Group 4: Clinical Implications - Previous studies indicated that the combination of pelareorep with gemcitabine, nab-paclitaxel, and atezolizumab achieved tumor response rates nearly three times higher than historical results [2] - If the mFOLFIRINOX combination yields similar positive outcomes, a broader range of metastatic PDAC patients may benefit from pelareorep-based therapy [2] Group 5: Future Directions - The GOBLET study aims to further investigate TIL expansion as a potential biomarker for clinical activity in patients treated with pelareorep [2][10] - Oncolytics is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [12][13]

Core Insights - The article discusses advancements in pancreatic cancer research and treatment, highlighting the importance of early detection and innovative therapies being developed by various biotech companies [1][2][3]. Group 1: Pancreatic Cancer Statistics and Research - Pancreatic cancer is one of the deadliest cancers, with up to 80% of patients diagnosed at late stages, making early detection crucial [1]. - The American Cancer Society estimates that approximately 66,440 individuals in the USA will be diagnosed with pancreatic cancer in 2024, with about 51,750 expected to die from the disease [1]. Group 2: Oncolytics Biotech Inc. Developments - Oncolytics Biotech's pelareorep has received Fast Track Designation from the FDA for pancreatic cancer treatment and is collaborating with the Global Coalition for Adaptive Research (GCAR) to evaluate its use as a first-line treatment for metastatic pancreatic ductal adenocarcinoma [2][3]. - The company is advancing research on pelareorep combined with modified FOLFIRINOX (mFOLFIRINOX) and Tecentriq, with a new study cohort cleared for patient enrollment [3][5]. Group 3: Other Biotech Companies and Innovations - Candel Therapeutics received FDA orphan drug designation for its CAN-2409 treatment in pancreatic cancer, which combines a specially engineered virus with valacyclovir to enhance immune response against tumors [6][8]. - AstraZeneca's drug Enhertu has received accelerated approval for treatment across multiple HER2-expressing solid tumors, including pancreatic cancer [9][10]. - Merus N.V. announced the FDA's acceptance of a Biologics License Application for zenocutuzumab, targeting NRG1+ pancreatic cancer, which may offer a substantial improvement over existing therapies [10][11]. - Lantern Pharma is collaborating with Oregon Therapeutics to optimize the development of XCE853, a first-in-class drug candidate for various cancers, including drug-resistant pancreatic cancer [12][13].

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 /PRNewswire/ -- USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as Johns Hopkins Medicine reports that up to 10% of patients diagnosed early can become disease-free after treatment. The American Cancer Society estimates that around 66,440 people ( ...

Core Points - Oncolytics Biotech Inc. held its Annual General Meeting (AGM) on May 15, 2024, with 41.34% of the issued and outstanding common shares represented [1] - All eight nominees proposed by the Corporation were elected as Directors, with voting percentages for each nominee ranging from 70.97% to 84.78% [2] - Shareholders approved all other resolutions, including fixing the number of directors at eight and appointing auditors for the upcoming year [2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses [4] - The company is conducting combination clinical trials with pelareorep in various malignancies and is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [5]

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with 97% accuracy. According to Johns Hopkins Medicine, up to 10% of patients who receive an early diagnosis become disease-free after treatment, meaning the earlier it's detected, the better the pati ...

FN Media Group News Commentary PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 Americans will be diagnosed with pancreatic cancer. It is estimated that 50,550 people will die from pancreatic cancer (26,620 men and 23,930 women). Pancreatic cancer is an aggressive form of cancer, and it is often not detected until it is in an advanced stage. Additio ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around ...

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic canc ...